REVIEW

Pharmacological approach for drug repositioning against cardiorenal diseases

Yoshito Zamami1,2, Masaki Imanishi2, Kenshi Takechi3, and Keisuke Ishizawa1,2

1Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan, 2Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan, 3Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan

Abstract: New applications of approved clinically used drugs are being discovered. Drug repositioning is a proposed strategy for developing these drugs as therapeutic agents for different diseases. Currently, approximately 2000 drugs are used in Japan. However, the compound targets and pathways involved in the pharmacological actions of 70-80% of these drugs have not been adequately clarified. Pharmacological examination of approved drugs is an important task in drug repositioning and vital for improving drug development efficiency. This review reports that angiotensin II type 1 receptor blockers show receptor-independent effects against reactive oxygen species generation in renal cells. Additionally, nitrosonifedipine has an antioxidative effect and protects endothelial cells against oxidative stress, and pioglitazone has multiple effects that improve dysfunctions in vascular control regulated by adrenergic and calcitonin gene-related peptide-containing nerves in animal models of diabetes. These data suggest that some approved drugs could be useful for treating cardiorenal diseases. Since cardiorenal diseases are likely to have chronic pathological conditions and require chronic drug administration, highly safe drugs are needed. Compared to newly developed drugs, drug repositioning of approved drugs with safety information is considered a particularly useful technique for searching new treatments for cardiorenal diseases. J. Med. Invest. 64 : 197-201, August, 2017

Keywords: Drug repositioning, pharmacology, cardiorenal diseases

INTRODUCTION

In recent years, new applications for approved drugs that are used clinically have been discovered. Therefore, drug repositioning has been proposed as a strategy for developing these drugs as therapeutic agents for different diseases (1). Approved drugs have already undergone clinical trials, and information on their safety and pharmacokinetics in humans is available. Therefore, in drug repositioning, it is possible to reduce the cost and shorten the duration of drug development while ensuring safety (1-3). Furthermore, since the pharmacokinetics of such drugs in humans have been clarified, gaps between animal studies and clinical trials are less likely to be found. Additionally, the success rates of developing such drugs are higher than those for new compounds.

Approximately 2000 drugs are currently reported to be used in Japan. However, 70-80% of these drugs have not been studied to determine their compound targets and mechanisms of action. Therefore, their pharmacological actions have not been adequately clarified. Pharmacological examination of approved drugs is an important task in drug repositioning. It is also an essential process that must be considered to improve the efficiency of drug development.

Cardiovascular disease (CVD) and chronic kidney disease (CKD, chronic renal disease) are closely related. The frequency of cardiovascular events was reported to increase with decreasing glomerular filtration rate (GFR) in a large resident health survey (4). In addition, background factors such as obesity, hypertension, diabetes, and dyslipidemia are known to reduce renal and cardiac functions. Furthermore, cardiovascular diseases are often chronic and frequently require medicines to be administered over a long period, and therefore, a high safety profile is required. However, there are no highly safe therapeutics for these cardiorenal diseases, which is a serious problem. In this review, we have summarized our data on pharmacological research aimed at repositioning drugs for the treatment of cardiorenal diseases (Fig 1).

Antioxidative effect of nifedipine photodegradation product in management of cardiorenal diseases

Nifedipine is a commonly used calcium channel blocker for treating hypertension; however, it is extremely light-sensitive. Nifedipine is converted to its nitroso analog nitrosonifedipine [2,6-dimethyl-4-(2-nitrosophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester] (NO-NIF) (5-7) after photolysis. NO-NIF does not have a calcium channel blocking effect; however, it has a strong and unique radical scavenging ability. It reacts with lipid-derived radicals in vitro and participates in radical scavenging activities in the cell membrane (8). We focused on this unique radical scavenging activity and previously investigated the effects of NO-NIF in some oxidative-stress-related cardiorenal diseases using animal models (10-12).

First, the study investigated whether NO-NIF exhibits a higher 1,1-diphenyl-2-picolylhydrazyl (DPPH) radical scavenging activity than nifedipine does. Interestingly, a mixture of NO-NIF and unsaturated fatty acids exhibited an extremely stronger radical scavenging activity than NO-NIF alone did (8). Furthermore, an electron paramagnetic resonance (EPR) method revealed that...
NO-NIF could be converted to its radical form through an in vitro reaction with unsaturated fatty acids, which are abundant in cell membranes, but not with saturated fatty acids. NO-NIF was also shown to be converted to its radical following a reaction with endothelial or vascular smooth muscle cells. EPR signals in the two cell types showed that the formation of NO-NIF radical continued for over 12 hours after the reaction stopped. In addition, characteristic acenotropic triplet signals suggested that the radical stayed within the cell membrane. Thus, it was proposed that NO-NIF shows a unique strong radical scavenging activity that is prolonged by reacting with unsaturated fatty acids, after which it is converted to its radical form in the cell membrane (8).

NO-NIF has also been shown to suppress the decrease in cell viability caused by cumene-hydroperoxide-induced membrane peroxidation in endothelial cells (9). NO-NIF also suppresses the expression of intercellular adhesion molecule (ICAM)-1 and the reduction in cell viability induced by tumor necrosis factor (TNF)-α in endothelial cells. Conversely, nifedipine does not similarly affect the decrease in cell viability. The results suggest that NO-NIF has a strong antioxidative effect and protects endothelial cells, which nifedipine does not exhibit.

Furthermore, the effects of NO-NIF have been investigated on the oxidative-stress-related pathogeneses of several cardiorenal diseases in mice. NO-NIF was shown to suppress protein urea excretion induced by Nω-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide synthase (NOS) (10). It also suppresses ICAM-1 expression in the rat aorta. However, similar amount of nifedipine did not exhibit any of these effects. Moreover, because NO-NIF did not affect L-NAME-induced hypertension, the observed effects occurred independently of blood pressure (10).

The effects of NO-NIF on angiotensin II (Ang II)-induced vascular remodeling have also been investigated. The results showed that NO-NIF suppressed Ang II-induced medial thickening by suppressing vascular smooth muscle cell proliferation, vascular fibrosis, and inflammation in the aortae of mice (11). In addition, it suppressed Ang II-induced superoxide generation in the aorta and the urinary excretion of 8-hydroxydeoxyguanosine (8-OHdG) (11). Additionally, previous in vitro studies revealed that NO-NIF suppressed Ang II-induced generation of reactive oxygen species (ROS), phosphorylations of epidermal growth factor receptor and AKT, and cell migration and proliferation (11). These results suggest that NO-NIF suppresses Ang II-induced vascular remodeling via suppressing oxidative stress in the aorta. In addition, NO-NIF suppressed Ang II-induced ICAM-1 expression in the aorta and Ang II-induced blood pressure elevation. Thus, it was concluded that NO-NIF has a protective effect on endothelial cells. Because NO-NIF showed a strong antioxidative effect and protected endothelial cells, its effects were further investigated in a mouse model of diabetic nephropathy. Although NO-NIF did not affect glucose tolerance, it suppressed urinary protein excretion, glomerular expansion, ICAM-1 induction in the glomeruli, superoxide generation in the kidney, and urinary excretion of 8-OHdG in KKay mice with type 2 diabetes (12). Thus, NO-NIF alleviated type 2 diabetic nephropathy via its antioxidative effect without affecting glucose tolerance. These results suggest that NO-NIF may be a potential new therapeutic agent for managing cardiorenal diseases.

Receptor-independent effects of angiotensin II receptor blockers on renal cells

Ang II type 1 receptor (AT1R) blockers (ARBs) are major therapeutic agents for treating hypertension. However, several reports have indicated that the beneficial effects of ARBs on cardiorenal diseases are independent of blood pressure (13, 14). It has been suggested that ARBs have a renoprotective effect in addition to blood pressure-reducing effects (13-15). In addition, ARBs have unique properties such as anti-apoptotic, antioxidant, and anti-inflammatory effects that are exerted in a receptor-independent manner (16-18).

Mesangial cell migration induced by platelet-derived growth factor (PDGF) has been shown to be inhibited by the ARB olmesartan (Olm); however, AT1R knockdown is not affected (19). Although results have shown that Olm does not exhibit a superoxide scavenging activity or affect the expression of PDGF receptors, it suppresses PDGF-induced ROS generation and its downstream phosphorylation pathway of Src and big mitogen-activated protein kinase 1 (BMK1), implicated in cell migration. Moreover, because Olm did not affect the hydrogen-peroxide-induced phosphorylation pathway, it is believed to affect PDGF-induced ROS generation but not its downstream phosphorylation pathway. Therefore, Olm has been proposed to suppress PDGF-induced ROS generation, leading to subsequent inhibition of Src/BMK1/migration in an AT1R-independent manner.

Next, an active metabolite of Olm, RNH-6270, has been shown to suppress TNF-α-induced cytotoxicity in glomerular endothelial cells (20). In addition, RNH-6270 suppressed cell death and the increase in ICAM-1 expression induced by TNF-α via inhibition of ROS in human glomerular endothelial cells. In summary, these results showed that the receptor-independent effects of ARBs are implicated in ROS generation in renal cells. Additionally, those effects may be beneficial in the management of cardiorenal diseases.
Ameliorating effect of pioglitazone in neurogenic vascular dysfunction in diabetes mellitus with insulin resistance

Pioglitazone is a thiazolidinedione derivative and a ligand for peroxisome proliferator-activated receptor-γ (PPARs). It is used in the treatment of diabetes mellitus with insulin resistance. Several studies have indicated that pioglitazone increases insulin sensitivity and inhibits the development of experimental hypertension (21-23). Therefore, active treatment with a PPARγ ligand is considered useful for treating insulin-resistant patients with complications such as hypertension and vascular disorders. Therefore, the ameliorating effects of pioglitazone on vascular control regulated by adrenergic and CGRPergic nerves have been investigated in diabetic rats.

First, acute insulin infusion has been demonstrated to augment adrenergic-nerve-mediated vasoconstriction and inhibit vasodilation mediated by calcitonin gene-related peptide (CGRP)-containing (CGRPergic) nerves in pithed rats without central vasoreflex (24, 25). Thus, insulin plays an important role in vascular control regulated by adrenergic and CGRPergic nerves.

Next, it has been demonstrated that rats administered 15% fructose solution as their drinking fluid showed a marked increase in plasma insulin levels but not a significant increase in blood glucose levels. Moreover, fructose-drinking rats (FDR) with hyperinsulinemia showed signs of hypertension. Thus, hypertension appears to be closely associated with chronic hyperinsulinemia and insulin resistance. Furthermore, it has been indicated that fructose-drinking pithed rats with chronic hyperinsulinemia show augmented adrenergic-nerve-mediated vasoconstriction and decreased CGRPergic-nerve-mediated vasodilatation (26-29). Based on the reports, insulin likely exerts a neurogenic regulatory effect on vascular tone.

Finally, oral administration of pioglitazone to FDRs for 2 weeks markedly decreased their plasma levels of insulin, triglycerides, and glucose. However, unreated FDRs remained hypertensive, whereas the blood pressure of pioglitazone-treated FDRs markedly decreased to a level similar to that of the control rats (30). Furthermore, treatment of FDRs with pioglitazone has been shown to restore the activation of adrenergic nerves and blunt CGRPergic-nerve-mediated vasodilator response; however, exogenous CGRP-induced responses are not affected (30). Therefore, insulin resistance is associated with dysfunctions of vascular control regulated by adrenergic and CGRPergic nerves.

In conclusion, pioglitazone has been suggested to exert multiple effects that improve insulin resistance and neurogenic vascular dysfunction in a rat model of diabetes. In addition, pharmacotherapy using pioglitazone has been suggested to have the potential to effectively prevent the development of hypertension in patients who have diabetes mellitus with insulin resistance.

CONCLUSION

Recently, numerous drug repositionings have succeeded, and various drugs with novel efficacies against intractable diseases have been discovered (Table 1). In this review, we highlighted that ARBs show receptor-independent effects against ROS generation in renal cells, NO-NIF has an antioxidative effect and protects endothelial cells from oxidative stress in some animal models, and pioglitazone has multiple effects that improve dysfunctions in vascular control regulated by adrenergic and CGRPergic nerves in animal models of diabetes. These data suggested that some approved drugs could be useful therapeutic agents for treating cardiorenal diseases.

Cardiorenal diseases are often chronic pathological conditions that require drug administration over prolonged, and therefore, highly safe drugs are needed. Compared to newly developed drugs, drug repositioning of approved drugs with available safety and efficacy information is considered a particularly useful technique for identifying new treatments for cardiorenal diseases. However, when an effective existing approved drug is out of patent, pharmaceutical companies are often reluctant to clinically apply because they cannot achieve profits. Therefore, drug repositioning should be promoted by researchers from countries and other sources.

Recently, a method of comprehensively analyzing the molecular effects of approved drugs using the latest analytical methods and examining their possibility as a therapeutic drug for other diseases is being carried out. In vitro systems such as high-throughput screening are used for efficacy discovery, and in silico systems based on drug and disease databases are often used for drug evaluation (31-36). The development of the research highlighted in this review using these latest analytical methods would lead to the clinical application of many therapeutic agents in the management of cardiorenal diseases.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Approved applications</th>
<th>New applications</th>
<th>Year of report</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetophenazine</td>
<td>schizophrenia</td>
<td>Prostate cancer</td>
<td>2007</td>
</tr>
<tr>
<td>Dutasteride</td>
<td>prostate</td>
<td>Alzheimer</td>
<td>2008</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>breast cancer</td>
<td>systemic lupus erythematosus</td>
<td>2009</td>
</tr>
<tr>
<td>Ibudilast</td>
<td>asthma</td>
<td>neuropsychiatric pain</td>
<td>2010</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>ulcer</td>
<td>lung cancer</td>
<td>2011</td>
</tr>
<tr>
<td>Aspirin</td>
<td>anticoagulation</td>
<td>Prostate cancer</td>
<td>2014</td>
</tr>
<tr>
<td>Ribavirin</td>
<td>antiviral</td>
<td>Suppression of cancer resistance</td>
<td>2015</td>
</tr>
<tr>
<td>Carperitide</td>
<td>cardiac failure</td>
<td>Metastasis of lung cancer</td>
<td>2015</td>
</tr>
<tr>
<td>Bezafibrate</td>
<td>hyperlipidemia</td>
<td>Activation of antitumor effect</td>
<td>2017</td>
</tr>
</tbody>
</table>

ACKNOWLEDGEMENTS

This study was supported by JSPS KAKENHI (15K07967).

CONFLICT OF INTEREST

The authors report no relationships that could be construed as a conflict of interest.

REFERENCE


